是由于孤独的化囊细胞粒瘤引起的
1Department of Neurology, CARE Hospitals, Banjara Hills, Hyderabad 500034, Telengana, India.
Pathogens (Basel, Switzerland)
|August 25, 2023
概括
在低收入国家,性神经囊病 (NCC) 导致大约30%的成人发病. 虽然确切的机制尚不清楚,焦点发作是常见的,但可以用药物治疗,与NCC相关的是可以预防的.
科学领域:
- 神经学 神经学
- 传染性疾病 传染性疾病
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 神经囊性 (NCC) 是低收入和中等收入国家的成年人 (>20岁) 获得的主要原因.
- 大约30%的成人发作和病例与NCC有关.
- 孤独化NCC是印度和拉丁美洲等地区成年的常见原因.
研究的目的:
- 审查化NCC在成人发作的作用.
- 讨论与NCC相关的发作机制和发作特征.
- 突出抗发作药物的有效性和NCC相关的可预防性.
主要方法:
- 关于神经囊病和的研究的文献综述.
- 对流行病学数据分析成年发作的原因.
- 关于NCC的发性潜力和治疗结果的当前理解的综合.
主要成果:
- 性NCC在许多成人病例中被强烈认为是致焦点.
- 焦点发作,有或没有意识受损,是主要的发作类型,可能演变为双边强力-克隆性发作.
- 抗发作药物,特别是单一治疗,在NCC相关中显示出良好的发作控制.
结论:
- 性NCC是成年发病的重要原因之一,特别是在流行地区.
- 了解NCC的发过程对于有针对性的干预至关重要.
- 与NCC相关的发作障碍是可以预防的,并且可以通过适当的治疗来管理,强调公共卫生战略.
关键词:
抗发作药物 抗发作药物发作状态 性 (Epilepticus) 是一种焦点发作的发作这是一个神经囊性神经病.一个人的化Cysticercus granulaomaoma.单独的化神经囊细胞结核病.更多相关视频
09:00Investigating the Function of Deep Cortical and Subcortical Structures Using Stereotactic Electroencephalography: Lessons from the Anterior Cingulate Cortex
Published on: April 15, 2015
12.4K
09:32Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
12.4K
相关概念视频
Seizures: Classification
411
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
411
Arteries of the Lower Limbs
213
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
213
Antiepileptic Drugs: Calcium Channel Blockers
453
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
453
Antiepileptic Drugs: Potassium Channel Activators
211
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
211
